Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Accounts Payables (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Accounts Payables for 3 consecutive years, with $416682.0 as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 50.25% to $416682.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $416682.0 through Dec 2025, down 50.25% year-over-year, with the annual reading at $416682.0 for FY2025, 50.25% down from the prior year.
  • Accounts Payables hit $416682.0 in Q4 2025 for Mangoceuticals, down from $526964.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.2 million in Q1 2025 to a low of $30796.0 in Q1 2023.
  • Historically, Accounts Payables has averaged $464943.1 across 3 years, with a median of $471823.0 in 2025.
  • Biggest YoY gain for Accounts Payables was 3266.23% in 2025; the steepest drop was 50.25% in 2025.
  • Year by year, Accounts Payables stood at $140765.0 in 2023, then soared by 494.96% to $837501.0 in 2024, then plummeted by 50.25% to $416682.0 in 2025.
  • Business Quant data shows Accounts Payables for MGRX at $416682.0 in Q4 2025, $526964.0 in Q3 2025, and $767996.0 in Q2 2025.